Bolenz, Christian and Herrmann, Edwin and Bastian, Patrick J. and Michel, Maurice S. and Wuelfing, Christian and Tiemann, Arne and Buchner, Alexander and Stief, Christian G. and Fritsche, Hans-Martin and Burger, Maximilian and Wieland, Wolf F. and Hoefner, Thomas and Haferkamp, Axel and Hohenfellner, Markus and Mueller, Stefan C. and Stroebel, Philipp and Trojan, Lutz (2010) Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. BJU INTERNATIONAL, 106 (4). pp. 493-498. ISSN 1464-4096,
Full text not available from this repository. (Request a copy)Abstract
OBJECTIVES To validate the association of lymphovascular invasion (LVI) with disease recurrence and cancer-specific survival (CSS) in a multicentre cohort of patients treated with radical cystectomy (RC) for urothelial bladder cancer (UBC). PATIENTS AND METHODS We collected pathological and clinical data on 1099 lymph node-negative patients treated with RC at six German institutions. LVI was defined as the presence of tumour cells within an unequivocal endothelium-lined space in haematoxylin and eosin-stained sections. RESULTS LVI was present in 295 (26.8%) patients; the presence of LVI correlated significantly with increasing tumour stage, i.e. pT1, 65 (29.4%); pT2, 88 (31.5%); pT3 110 (31.8%); and pT4 32 (38.1%) (P = 0.002) and grade (P < 0.001). In univariable analysis the presence of LVI was significantly associated with reduced recurrence-free survival (P = 0.008) and reduced CSS (P = 0.039). On multivariable Cox regression analysis tumour stage (P < 0.001), age (> 75 vs >= 75 years; P = 0.018) and LVI (P < 0.001) were identified as independent predictors of CSS. CONCLUSIONS Our large multicentre study confirms the independent prognostic value of LVI in patients with node-negative UBC. LVI can be regarded as a surrogate variable for lymphatic micrometastasis in node-negative UBC. Assessment of LVI might improve the selection of patients who are likely to benefit from adjuvant therapy after RC. The identification of factors involved in the process of LVI could reveal new therapeutic targets for UBC.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CHEMOTHERAPY FOLLOWING CYSTECTOMY; TRANSITIONAL-CELL CARCINOMA; PROGNOSTIC-SIGNIFICANCE; ADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIAL; TRANSURETHRAL RESECTION; SURVIVAL; SPECIMENS; RECURRENCE; BIOMARKERS; bladder cancer; urothelial carcinoma; lymphovascular invasion; lymphatic metastasis; prognosis; survival |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 20 Jul 2020 06:52 |
| Last Modified: | 20 Jul 2020 06:52 |
| URI: | https://pred.uni-regensburg.de/id/eprint/24350 |
Actions (login required)
 |
View Item |
